HOME arrow News & PR

News & PR

RegeneRx Announces First Patient Enrolled in Phase 3 U.S. Neurotrophic Keratopathy (NK) Clinical Trial with RGN-259

2015.09.21
RegeneRx Announces First Patient Enrolled in Phase 3 U.S. Neurotrophic Keratopathy (NK) Clinical Trial with RGN-259
(if you want to view the body of article, click on the bottom link)
http://www.prnewswire.com/news-releases/regenerx-announces-first-patient-enrolled-in-phase-3-us-neurotrophic-keratopathy-nk-clinical-trial-with-rgn-259-300146089.html